Jaguar Health Inc
NASDAQ:JAGX
Jaguar Health Inc
NASDAQ:JAGX
Price:
4.22 USD
-1.63%
Market Closed
Updated:
Jun 1, 2024
Section:
Relative Value
The Relative Value of one
JAGX
stock under the Base Case scenario is
5.97
USD.
Compared to the current market price of 4.22 USD,
Jaguar Health Inc
is
Undervalued by 29%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
JAGX
Relative Value
Base Case
5.97
USD
Undervaluation 29%
Valuation Multiples
Multiples Across Competitors
JAGX Competitors Multiples
Jaguar Health Inc Competitors
Jaguar Health Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Jaguar Health Inc
NASDAQ:JAGX
|
1.2B USD | 114.9 | -30.4 | -38.8 | -36.4 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
779.7B USD | 21.7 | 127 | 62.1 | 70.7 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 16.9 | 46.3 | 34.5 | 37.9 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
353B USD | 4.1 | 9.2 | 11.3 | 14.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
318B USD | 5.2 | 137.9 | 34.4 | 56.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
189B GBP | 5.1 | 38 | 174.7 | 278.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
184.2B CHF | 3.1 | 16 | 9.1 | 10.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.3B CHF | 3.4 | 11.5 | 8.8 | 12.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
162.4B USD | 2.9 | -525.6 | 12.7 | 20.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
